• Tigen exercises its license option for the development of a Neoantigen-specific Tumor Infiltrating Lymphocytes product (currently in P-I trial for solid tumors) under collaboration with the Ludwig Institute for Cancer Research, CHUV, and the University of Lausanne
• The collaboration will be expanded to include technical and clinical development to bring the program to the next level of development
• The agreement focuses to deliver safe and effective treatments to patients & will further develop the treatment with their technical, clinical, and regulatory expertise to provide novel therapies to patients globally

Ref: Tigen | Image: Tigen